Santolaya María E, Alvarez Ana M, Avilés Carmen L, Becker Ana, Cofré José, Cumsille Miguel A, O'Ryan Miguel L, Payá Ernesto, Salgado Carmen, Silva Pamela, Tordecilla Juan, Varas Mónica, Villarroel Milena, Viviani Tamara, Zubieta Marcela
Department of Pediatrics, University of Chile, Los Huasos 1948, Las Condes, Santiago, Chile.
J Clin Oncol. 2004 Sep 15;22(18):3784-9. doi: 10.1200/JCO.2004.01.078.
To compare outcome and cost of ambulatory versus hospitalized management among febrile neutropenic children at low risk for invasive bacterial infection (IBI).
Children presenting with febrile neutropenia at six hospitals in Santiago, Chile, were categorized as high or low risk for IBI. Low-risk children were randomly assigned after 24 to 36 hours of hospitalization to receive ambulatory or hospitalized treatment and monitored until episode resolution. Outcome and cost were determined for each episode and compared between both groups using predefined definitions and questionnaires.
A total of 161 (41%) of 390 febrile neutropenic episodes evaluated from June 2000 to February 2003 were classified as low risk, of which 149 were randomly assigned to ambulatory (n = 78) or hospital-based (n = 71) treatment. In both groups, mean age (ambulatory management, 55 months; hospital-based management, 66 months), sex, and type of cancer were similar. Outcome was favorable in 74 (95%) of 78 ambulatory-treated children and 67 (94%) of 71 hospital-treated children (P = NS). Mean cost of an episode was US 638 dollars (95% CI, 572 dollars to 703 dollars) and US 903 dollars (95% CI, 781 dollars to 1,025 dollars) for the ambulatory and hospital-based groups, respectively (P =.003).
For children with febrile neutropenia at low risk for IBI, ambulatory management is safe and significantly cost saving compared with standard hospitalized therapy.
比较侵袭性细菌感染(IBI)低风险的发热性中性粒细胞减少儿童门诊治疗与住院治疗的疗效及成本。
智利圣地亚哥六家医院的发热性中性粒细胞减少患儿被分为IBI高风险或低风险。低风险患儿在住院24至36小时后被随机分配接受门诊或住院治疗,并监测至病情缓解。确定每个病例的疗效和成本,并使用预定义的定义和问卷在两组之间进行比较。
2000年6月至2003年2月评估的390例发热性中性粒细胞减少病例中,共有161例(41%)被归类为低风险,其中149例被随机分配接受门诊(n = 78)或住院(n = 71)治疗。两组患儿的平均年龄(门诊治疗组为55个月;住院治疗组为66个月)、性别和癌症类型相似。78例门诊治疗患儿中有74例(95%)疗效良好,71例住院治疗患儿中有67例(94%)疗效良好(P = 无显著差异)。门诊组和住院组每个病例的平均成本分别为638美元(95%可信区间,572美元至703美元)和903美元(95%可信区间,781美元至1025美元)(P =.003)。
对于IBI低风险的发热性中性粒细胞减少儿童,与标准住院治疗相比,门诊治疗安全且显著节省成本。